Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
94 hedge funds and large institutions have $226M invested in Marinus Pharmaceuticals, Inc in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 7 closing their positions.
286% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 7
111% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 18
72% more capital invested
Capital invested by funds: $131M → $226M (+$94.9M)
27% more funds holding
Funds holding: 74 → 94 (+20)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
42% less call options, than puts
Call options by funds: $819K | Put options by funds: $1.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$13.2M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$11M |
| 3 |
LPC
Lion Point Capital
New York
|
+$10.3M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$4.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.11M |
| 2 |
VA
VR Adviser
New York
|
-$1.79M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$708K |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$619K |
| 5 |
JP Morgan Chase
New York
|
-$611K |
MRNS Hedge Fund Activity: Q2 2020 in Review
94 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2020, worth a combined $226M — up 72% from $131M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new MRNS positions and 7 closed out — a net gain of 20 holders — while 38 added to existing stakes and 18 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $13.2M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $2.11M sold.
- 94 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2020, up from 74 in Q1 2020.
- Funds reported $226M of Marinus Pharmaceuticals, Inc stock for Q2 2020, up 72% quarter-over-quarter.
- 27 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2020 and 7 closed out, a net change of +20 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2020 was Avoro Capital Advisors, an estimated $13.2M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2020 was Acuta Capital Partners, an estimated $2.11M sold.
Based on aggregated 13F filings for Q2 2020.